TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04129905

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNP blood sample test
Description: Performed during normal recommended follow-up of the HCM patients.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electrocardiogram
Description: Performed during normal recommended follow-up of the HCM patients.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Holter ECG
Description: Performed during normal recommended follow-up of the HCM patients.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Performed during normal recommended follow-up of the HCM patients. Echocardiography at rest and during exercise.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Air venous plethysmography
Description: Performed specifically for the research. Non invasive, and non painful test evaluating different parameters of venous filling by inflation of an armband around the leg, upright positioning, flexion-extension of the leg. Total duration estimated at 30-45 minute.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Air venous plethysmography
Description: Performed specifically for the research. Non invasive, and non painful test evaluating different parameters of venous filling by inflation of an armband around the leg, upright positioning, flexion-extension of the leg. Total duration estimated at 30-45 minute.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Upper member arterial Doppler echography with analysis of FMD
Description: Performed specifically for the research. Measurement of the evolution of brachial artery diameter before and after inflation of a armband during 5 minutes. Non invasive and non painful test, duration 30 minutes.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Upper member arterial Doppler echography with analysis of FMD
Description: Performed specifically for the research. Measurement of the evolution of brachial artery diameter before and after inflation of a armband during 5 minutes. Non invasive and non painful test, duration 30 minutes.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Endothelial function biomarkers
Description: Performed specifically for the research. Blood sample test, 5 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endothelial function biomarkers
Description: Performed specifically for the research. Blood sample test, 5 minutes.
Study: NCT05190601

Intervention type: DEVICE
Intervention: uroflowmetry
Description: Qmax(ml/s),Qav(ml/s),Volume (ml)
Study: NCT01817101

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acid supplementation
Description: Gelatine capsule, 1 at each meals (3 per day) during one year
Study: NCT02740543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate HFA 220
Description: Subjects will take two (2) puffs of Fluticasone propionate HFA 220 twice a day.
Study: NCT01286987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Oral capsule with multiple dosage forms given once daily
Study: NCT00004142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine
Description: Part of hepatic arterial chemotherapy on days 1-7. Treatment repeats every 5 weeks for 6 courses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5-FU)
Description: Part of hepatic arterial chemotherapy over 1 hour on days 15, 22, and 29. Treatment repeats every 5 weeks for 6 courses.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional surgery
Description: Open laparotomy to identify target tumor in liver using intraoperative ultrasound.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Radiofrequency tissue ablation over 20 minutes to each tumor.
Study: NCT03446053

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-Rephasin® SAL200
Description: continuous intravenous infusion over 60 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: INT200-Placebo
Description: Formulation buffer except active ingredient for continuous intravenous infusion over 60 minutes
Study: NCT01391598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At lidocaine group 20 pacients will receive lidocaine at a dose of 4 mg / kg, not exceeding a dose of 240 mg diluted in 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study..:Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lidocaine
Description: After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At saline group 20 pacients will receive 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study. Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
Study: NCT04657640

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron and folic acid (IFA)
Description: Weekly regimen of one tablet containing Iron (60mg) and Folic Acid (2800 μg) for 3 months intermittently

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple Micronutrient Supplements (MMS) and loading dose of Iron and Folic Acid (IFA)
Description: Daily regimen of MMS for 3 months intermittently. MMS is the United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) tablet containing fifteen micronutrients including iron (30mg), folic acid (400 mcg), Vit A, Retinol (800 RE), vit D (200 IU), vit E (10 mg), vit C (70 mg), vit B1 (1.4 mg), vit B2 (1.4 mg), vit B6 (1.9 mg), vit B12 (2.6 mcg), niacin (18 mg), zinc (15 mg), copper (2 mg), iodine (150 mcg), selenium (65 mcg).~For the first 5 weeks of the study, participants will also receive weekly regimen of one tablet containing Iron (60mg) and Folic Acid (2800 μg) as a loading dose, in addition to daily MMS.
Study: NCT03521713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPORON
Description: * Strength : 3000 IU/0.3 mL, 5000 IU/0.5 mL, 6000IU/0.6 mL~* Formulation : Solution in PFS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPREX
Description: * Strength : 2000 IU/0.3 mL, 3000 IU/0.5 mL, 4000IU/0.6 mL~* Formulation : Solution in PFS
Study: NCT00538486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: Telmisartan 80mg 1/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan
Description: Candesartan 8mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan plus Metformin
Description: Candesartan 8mg 1/d Metformin 250mg 2/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine 5mg 1/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine plus Metformin
Description: Amlodipine 5mg 1/d, Metformin 250mg 2/d
Study: NCT06178835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: 500 IU/kg of erythropoietin is given 3 times for each patient: the day before surgery, start of surgery and on postoperative day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: The same amount of normal saline is given 3 times for each patient: the day before surgery, start of surgery and on postoperative day 1.
Study: NCT01462851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05297909 25 mg
Description: Single oral (PO) dose, PF-05297909 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05297909 100 mg
Description: Single oral (PO) dose, PF-05297909 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05297909 250 mg
Description: Single oral (PO) dose, PF-05297909 250 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05297909 525 mg
Description: Single oral (PO) dose, PF-05297909 525 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05297909 525 mg
Description: Single oral (PO) dose, 525 mg
Study: NCT03586076

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JHL1922
Description: Single doses of JHL1922 2.5 mg and then 10 mg per eRapid nebulizer

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: dornase alfa
Description: Single doses of Pulmozyme® 2.5 mg and then 10 mg per eRapid nebulizer
Study: NCT04651647

Intervention type: PROCEDURE
Intervention: Revision surgery with / without open bone graft
Description: Removal of previous implant and re-alignment and re-fixation using intramedullary nail with (bone graft group) / without (non bone graft group) open bone graft

Intervention type: PROCEDURE
Intervention: Revision surgery with / without open bone graft
Description: Removal of previous implant and re-alignment and re-fixation using intramedullary nail with (bone graft group) / without (non bone graft group) open bone graft
Study: NCT02356042

Intervention type: OTHER
Intervention: Geriatric inclusive art (GIA) activity
Description: The frequency of GIA sessions in this study was from 1 to 2 per month. The time of a session was around 1 hour 30 minutes. Participants of intervention group benefited GIA activity during a 6-month follow-up period.
Study: NCT03607994

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HIRREM-SOP
Description: HIRREM-SOP is an updated version of HIRREM. It is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.

Intervention type: DEVICE
Group type: OTHER
Intervention: HIRREM-SOP
Description: HIRREM-SOP is an updated version of HIRREM. It is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.

Intervention type: DEVICE
Group type: OTHER
Intervention: NCC
Description: Nonspecific acoustic stimulation with randomly generated tones not linked to brain activity.
Study: NCT02358928

Intervention type: OTHER
Group type: OTHER
Intervention: Diet Intervention
Study: NCT01031940

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: macintosh laryngoscope
Description: intubate with the macintosh laryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-MAC laryngoscope
Description: intubate with the C-MAC laryngoscope
Study: NCT04202055

Intervention type: OTHER
Intervention: Biomarker analysis
Description: Detection of biomarker in cerebrospinal fluid

Intervention type: OTHER
Intervention: Biomarker analysis
Description: Detection of biomarker in cerebrospinal fluid

Intervention type: OTHER
Intervention: Biomarker analysis
Description: Detection of biomarker in cerebrospinal fluid

Intervention type: OTHER
Intervention: Biomarker analysis
Description: Detection of biomarker in cerebrospinal fluid
Study: NCT01084811

Intervention type: PROCEDURE
Intervention: biopsy
Description: One or more biopsies from nasal mucosa will be harvested during surgery

Intervention type: PROCEDURE
Intervention: biopsy
Description: One or more biopsies from nasal mucosa will be harvested during surgery
Study: NCT03263312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise training all patients enrolled.
Study: NCT04322058

Intervention type: OTHER
Intervention: The Dads' Club
Description: The core intervention is Core 24/7 workshop attendance
Study: NCT03508193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional therapy
Description: Whole-foods based smoothie designed to emulate formulas used in EEN
Study: NCT03043495

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided supraclavicular brachial plexus block
Description: ultrasound guided Supraclavicular brachial plexus block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided supraclavicular brachial plexus block
Description: ultrasound guided Supraclavicular brachial plexus block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided supraclavicular brachial plexus block
Description: ultrasound guided Supraclavicular brachial plexus block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided supraclavicular brachial plexus block
Description: ultrasound guided Supraclavicular brachial plexus block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Various doses of Dexamethasone (2, 4 \& 8 mg) to be used as an Adjuvant to Local anesthetic drugs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Various doses of Dexamethasone (2, 4 \& 8 mg) to be used as an Adjuvant to Local anesthetic drugs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Various doses of Dexamethasone (2, 4 \& 8 mg) to be used as an Adjuvant to Local anesthetic drugs
Study: NCT01135914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: Ranibizumab 0.5 mg fixed loading dose via intravitreal injection, given once per month for 3 consecutive months (Day 1, Month 1 and Month 2). This treatment could be reapllied, depending on symptoms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: Ranibizumab 0.5 mg fixed loading dose via intravitreal injection, given once per month for 3 consecutive months (Day 1, Month 1 and Month 2). This treatment could be reapllied, depending on symptoms.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Laser photocoagulation treatment was administered on Day 1. Subsequent laser treatments could be administered if needed, in accordance with Early Treatment Diabetic Retinopathy Study (ETDRS) guidelines.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: Laser photocoagulation treatment was administered on Day 1. Subsequent laser treatments could be administered if needed, in accordance with Early Treatment Diabetic Retinopathy Study (ETDRS) guidelines.
Study: NCT02078102

Intervention type: DRUG
Group type: OTHER
Intervention: Meloxicam
Description: 15 mg tablets of Meloxicam will be taken orally in the morning, with or without food.

Intervention type: DRUG
Group type: OTHER
Intervention: Filgrastim
Description: Filgrastim will be subcutaneously injected in one or two sites at home.
Study: NCT00642148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW856553
Description: Active tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet and inhaler

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet and inhaler
Study: NCT01084811

Intervention type: PROCEDURE
Intervention: biopsy
Description: One or more biopsies from nasal mucosa will be harvested during surgery
Study: NCT00642148

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablet and inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide
Description: Active comparator inhaler
Study: NCT00885638

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 100 mg sitagliptin before ingestion of macronutrient

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A placebo tablet is given before ingestion of macronutrients
Study: NCT01031940

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq device
Description: intubate with the Airtraq device
Study: NCT00402714

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: extracorporeal photopheresis
Description: Extracorporeal photopheresis (ECP) is the ex vivo exposure of the leukocyte rich fraction to ultraviolet light in the presence of 8-methoxypsoralen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentostatin
Description: pentostatin 8mg/m2 over 48 hours by continuous infusion

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total Body Irradiation
Description: 600cGy TBI in 3 200cGy TBI fractions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentostatin
Description: pentostatin 8mg/m2 over 48 hours by continuous infusion

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total Body Irradiation
Description: 600cGy TBI in 3 200cGy TBI fractions
Study: NCT01511328

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HPV testing
Description: Testing for Human Papilloma Virus
Study: NCT01591421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: PO; Once daily starting day 1 cycle 1, or 5 out of 7 days every week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: IV; Every two weeks starting day 1 cycle 1 (i.e. day 1 and 15 each 28 day cycle)
Study: NCT02032693

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Everycell™

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01964599

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: PF-RS
Description: n=20 will consume PF-RS containing 30 g potato fiber for 14 days and will consume a control containing no fiber for 14 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: PF-RO1
Description: n=20 will consume PF-RO1 containing 30 g potato fiber for 14 days and will consume a control containing no fiber for 14 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: PF-RO2
Description: n=20 will consume PF-RO2 containing 30 g potato fiber for 14 days and then will consume a control containing no fiber for 14 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Control

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Control
Study: NCT03637036

Intervention type: OTHER
Group type: OTHER
Intervention: Communication intervention
Description: The intervention is a communication inviting staff to take up the influenza vaccination. Different versions of the communication are created, and the investigators will compare uptake rates between staff that received different letters.
Study: NCT01583166

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 10ml 0.5% bupivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 10ml 0.9% sodium chloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: 1:200,000 epinephrine
Study: NCT01052935

Intervention type: BIOLOGICAL
Group type: NO_INTERVENTION
Intervention: Group B streptococcus (GBS) vaccine
Description: No vaccine will be administered in this study. Only one study visit is required.~Subjects will return to the clinic for a single visit at 24 months (± 3 months) after the last injection administered in the V98P1 study.
Study: NCT00794807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alefacept
Description: Alefacept=LFA-3/IgG1 fusion protein, once weekly, 15mg i.m.
Study: NCT04205669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzyl Benzoate 25% Topical Application Lotion
Description: Applied to skin for the treatment of scabies
Study: NCT01964599

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Control
Study: NCT03386786

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Partner
Description: Health Partner is a combination of a mobile application and a web-based portal.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Care
Description: Patients randomized to Control will receive pre-printed brochures that outline the steps of the care plan for unilateral TKA and THA, as per standard care provided to any unilateral TJA patient receiving care at Princeton Healthcare System (PHCS).
Study: NCT02721121

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: circumferential pulmonary vein isolation
Study: NCT02891460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 40 mg MMC in 40 mL TC-3.
Description: A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature) for drug retention in the urinary bladder.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 80 mg MMC in 40 mL TC-3.
Description: A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature) for drug retention in the urinary bladder.
Study: NCT02721121

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Linear ablation in addiction to circumferential pulmonary vein isolation
Study: NCT04094649

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Vagus Nerve Stimulation (DECIMA)
Description: This is a single-site, double-blind, randomized, prospective, sham-controlled, crossover early feasibility study to determine whether ultrasound Vagus Nerve Stimulation (uVNS) inhibits postprandial hyperglycemia in humans.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Ultrasound Vagus Nerve Stimulation (DECIMA)
Description: This is a single-site, double-blind, randomized, prospective, sham-controlled, crossover early feasibility study to determine whether ultrasound Vagus Nerve Stimulation (uVNS) inhibits postprandial hyperglycemia in humans.